Updates in the Management of Graves Disease in Children

Area of Science:

• Pediatric Endocrinology
• Autoimmune Diseases
• Thyroid Disorders

Background:

• Graves disease (GD) is the leading cause of hyperthyroidism in children.
• Current treatments include antithyroid drugs (ATD), radioactive iodine, and surgery, with limited changes over time.
• Most pediatric patients require definitive treatment due to low spontaneous remission rates with ATD.

Purpose of the Study:

• To review recent clinical trials and systematic reviews on long-term outcomes of established GD treatments in children.
• To discuss novel and emerging targeted therapies for pediatric Graves disease.
• To provide an overview of the latest developments in managing childhood GD.

Main Methods:

• Systematic review of recent clinical trials.
• Analysis of long-term outcomes for ATD therapy, radioactive iodine, and surgery.
• Inclusion of data on emerging targeted therapies for GD.

Main Results:

• Established treatments (ATD, radioactive iodine, surgery) have known long-term outcomes in pediatric GD.
• Novel therapies targeting B-cells and the TSH receptor are under investigation.
• The definitive role of new therapies in childhood GD is yet to be established.

Conclusions:

• Pediatric Graves disease management relies on established therapies with varying long-term implications.
• Emerging targeted therapies offer potential new avenues for treatment.
• Further research is needed to establish the efficacy and safety of novel GD treatments in children.